Sol-Gel Technologies (SLGL) Other Non Operating Income (2021 - 2023)

Sol-Gel Technologies' (SLGL) quarterly Other Non Operating Income came in at $41000.0 in Q4 2023, up 192.86% on a QoQ basis from $14000.0 in Q3 2023.

Sol-Gel Technologies (SLGL) Other Non Operating Income (2021 - 2023) Analysis & Trends

Sol-Gel Technologies (SLGL) has 2 years of Other Non Operating Income data on file, last reported at $41000.0 in Q4 2023.

On a quarterly basis, Other Non Operating Income changed N/A year-over-year to $41000.0 in Q4 2023; TTM through Dec 2023 was $579000.0, a N/A change from a year earlier, with the FY2023 full-year figure at $55000.0, changed N/A from the prior year.
Other Non Operating Income for Q4 2023 stood at $41000.0, up from $14000.0 in the prior quarter.
Over the last five years, Other Non Operating Income for SLGL reached as high as $554000.0 in Q3 2021 and fell as low as -$30000.0 in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Sol-Gel Technologies	227.58 Mn	217.44 Mn	-

Download Data